Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 54.6B 63.65B 8.12B 6.96B 6.51B 5.95B 11.23B 778B 11.35B 77.05B 29.96B 391B 30.49B 29.83B 1,292B P/E 2026 *
39.3x
P/E 2027 * 31.9x
Enterprise Value 49.55B 57.76B 7.37B 6.32B 5.91B 5.4B 10.19B 706B 10.3B 69.92B 27.19B 354B 27.67B 27.08B 1,173B EV / Sales 2026 *
6.08x
EV / Sales 2027 * 5.16x
Free-Float
61.13%
Yield 2026 *
0.93%
Yield 2027 * 1.15%
04:50am CIG Shanghai's H1 Profit More Than Doubles MT
04:31am Asymchem Laboratories' H1 Profit Declines 16% MT
08-24 Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
07-31 Asymchem Laboratories to Subscribe for Subsidiary's New Shares for 1.05 Billion Yuan; Shares Up 6% MT
07-30 Shanghai Asymchem Biotechnology Development Co., Ltd. announced that it expects to receive CNY 1.239699995 billion in funding from Asymchem Laboratories Co., Ltd., Suzhou Gao Ling Qirui Healthcare Investment, L.P. and another investor CI
07-27 AsymBio, Subsidiary of Asymchem Group Kicks Off Construction of Fengxian R&D Building CI
07-10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 175.98 Yuan From 132.37 Yuan, Keeps at Buy MT
07-10 Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$131.48 From HK$115.43, Keeps at Buy MT
06-11 Asymchem Laboratories Co., Ltd. Approves Final Profit Distribution Plan to Be Implemented (A Shares) for 2025, Payable on June 26, 2026 CI
05-27 Asymbio Showcases Comprehensive Conjugation Toolbox to Support Process Development for Next-Generation Bioconjugates CI
05-20 Citigroup's long position in H shares of Asymchem Laboratories (Tianjin) decreases to 4.99% on May 14 from 5.66%, HKEX filing says RE
05-15 Asymchem Laboratories Co., Ltd. Recommends Final Dividend for the Year Ended 31 December 2025, Payable on 24 July 2026 CI
05-13 Citigroup's long position in H-shares of Asymchem Laboratories (Tianjin) decreases to 5.36% on May 7, HKEX says RE
1 day-7.26%
1 week-8.86%
Current month-0.18%
1 month-3.81%
3 months+13.72%
6 months+37.93%
Current year+56.04%
1 week 109.4
Extreme 109.4
139.7
1 month 105
Extreme 105
139.7
Current year 69.2
Extreme 69.2
139.7
1 year 69.2
Extreme 69.2
139.7
3 years 37.6
Extreme 37.6
139.7
5 years 37.6
Extreme 37.6
277.14
10 years 37.6
Extreme 37.6
277.14
Manager TitleAgeSince
Chief Executive Officer 70 07/10/1998
Chief Executive Officer 49 19/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 18/07/2011
Chairman 70 07/10/1998
Director/Board Member 65 18/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-7.26%-8.86% - - 8.72B
-0.67%+5.39%+75.21%+127.54% 1,119B
+1.04%+4.07%+52.29%+65.39% 651B
-0.17%+5.67%+25.60%+80.40% 468B
-1.38%+4.02%+41.64%+42.38% 374B
-0.52%+2.72%+24.32%+41.06% 302B
-1.06%+4.76%+1.19%+12.65% 259B
+1.03%+5.83%+51.11%+72.96% 238B
-0.53%+2.34%-17.77%-53.66% 208B
+0.42%+5.63%+27.86%+92.24% 181B
Average -0.91%+4.81%+31.27%+53.44% 422.21B
Weighted average by Cap. -0.25%+4.95%+43.93%+72.99%

Financials

2026 *2027 *
Net sales 8.07B 9.4B 1.2B 1.03B 962M 880M 1.66B 115B 1.68B 11.38B 4.43B 57.7B 4.51B 4.41B 191B 9.48B 11.05B 1.41B 1.21B 1.13B 1.03B 1.95B 135B 1.97B 13.38B 5.2B 67.81B 5.3B 5.18B 224B
Net income 1.43B 1.67B 213M 183M 171M 156M 295M 20.42B 298M 2.02B 787M 10.25B 801M 783M 33.93B 1.77B 2.06B 263M 226M 211M 193M 364M 25.2B 368M 2.5B 971M 12.65B 988M 967M 41.87B
Net Debt -5.05B -5.89B -751M -644M -602M -551M -1.04B -71.92B -1.05B -7.13B -2.77B -36.11B -2.82B -2.76B -119B -4.39B -5.12B -653M -560M -524M -479M -904M -62.56B -913M -6.2B -2.41B -31.41B -2.45B -2.4B -104B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Date Price Change Volume
24/08/26 HK$111.10 -7.26% 1,726,000
21/08/26 HK$119.80 -7.49% 1,991,240
20/08/26 HK$129.50 +2.37% 3,046,941
19/08/26 HK$126.50 -1.17% 1,073,840
18/08/26 HK$128.00 +5.00% 1,278,068
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
156.57CNY
Average target price
169.35CNY
Spread / Average Target
+8.16%

Quarterly revenue - Rate of surprise